Literature DB >> 8660670

The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.

M D Esposti1, A Ngo, A Ghelli, B Benelli, V Carelli, H McLennan, A W Linnane.   

Abstract

We have studied the interaction of idebenone (2,3-dimethoxy-5-methy-6-(10-hydroxy)decyl-1,4-benzoquinone) with the energy-conserving complexes of the respiratory chain in beef heart mitochondria and compared its energetic efficiency with that of other analogs of coenzyme Q. Idebenone is a very effective substrate for succinate:Q reductase and ubiquinol:cytochrome c reductase, but it is clearly a poor substrate for NADH:Q reductase (complex I). Indeed, idebenone is a strong inhibitor of both the redox and proton pumping activity of complex I, showing effects in part similar to those of coenzyme Q-2. However, the mechanism of idebenone interaction with complex I may be different from that of Q-2 because of its different sensitivity to inhibitors. The possible relevance of the present findings to the therapeutic use of idebenone is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660670     DOI: 10.1006/abbi.1996.0267

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  30 in total

1.  Loss of cytochrome c oxidase activity and acquisition of resistance to quinone analogs in a laccase-positive variant of Azospirillum lipoferum.

Authors:  G Alexandre; R Bally; B L Taylor; I B Zhulin
Journal:  J Bacteriol       Date:  1999-11       Impact factor: 3.490

Review 2.  Novel therapeutic approaches for Leber's hereditary optic neuropathy.

Authors:  Shilpa Iyer
Journal:  Discov Med       Date:  2013-03       Impact factor: 2.970

Review 3.  Coenzyme Q and mitochondrial disease.

Authors:  Catarina M Quinzii; Michio Hirano
Journal:  Dev Disabil Res Rev       Date:  2010

4.  Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines.

Authors:  Constance J Glover; Alfred A Rabow; Yasemin G Isgor; Robert H Shoemaker; David G Covell
Journal:  Biochem Pharmacol       Date:  2006-10-13       Impact factor: 5.858

5.  Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects.

Authors:  Luis C López; Catarina M Quinzii; Estela Area; Ali Naini; Shamima Rahman; Markus Schuelke; Leonardo Salviati; Salvatore Dimauro; Michio Hirano
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

Review 6.  Idebenone: an emerging therapy for Friedreich ataxia.

Authors:  Thomas Meier; Gunnar Buyse
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

7.  Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone).

Authors:  H Rauchová; Z Drahota; C Bergamini; R Fato; G Lenaz
Journal:  J Bioenerg Biomembr       Date:  2008-03-27       Impact factor: 2.945

8.  Decylubiquinol impedes mitochondrial respiratory chain complex I activity.

Authors:  Paule Bénit; Abdelhamid Slama; Pierre Rustin
Journal:  Mol Cell Biochem       Date:  2008-04-15       Impact factor: 3.396

9.  Treatment of mitochondrial disorders.

Authors:  Sreenivas Avula; Sumit Parikh; Scott Demarest; Jonathan Kurz; Andrea Gropman
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

10.  Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species.

Authors:  Martin S King; Mark S Sharpley; Judy Hirst
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.